Bad Vilbel, Hesse, Germany
Industry executive with leadership roles in Corporate Development, Strategy and M&A at Boehringer Ingelheim, Heraeus, Lianhetech, EY and Xelium. Passionate about business transformation in particular fast growing businesses, technology plays and geographical expansion. Strong network to key players in the Life Science, Chemical and Renewable sectors. Worked globally and lived in Germany, Australia, Singapore, China and UK.
Xelium is an advisory firm in Life Science focused on Strategy Consulting and Mergers & Acquisitions Advisory. Advising international clients on strategy, acquisitions, divestitures, restructurings, licensing opportunities in the Life Science sector. Selected references 1. Strategic review, creation of strategic and financial plan for a CDMO business 2. Development and execution of buy-and-build strategy for a European based CDMO in API manufacturing that resulted in there acquisitions 3. Creation of strategic, commercial and financial plan for a R&D/manufacturing services business in biologics, vaccines and ATMPs. 4. Finance raise: Performed strategy, business planning and valuation for a cell line development company. Approached finanical investors and negotiated term sheets/contracts. Advised on due diligence preparation and management presentation. 5. Sell side advisory for an international Life Science supplier business 6. Advised founder led business on integration of add-on acquisitions 7. PE buyside advisory in the API manufacturing sector
The Ofichem Group is a pharmaceutical company headquartered in Ter Apel, the Netherlands serving the human pharma and veterinary market. The Group of companies provides services all around active pharmaceutical ingredients such as cGMP manufacturing in small and large quantities, own API portfolio, R&D and analytical services, distribution, and packaging.
Advising international clients on acquisitions, divestitures, restructurings, licensing and business development opportunities in the Life Science sector. Execution of site divestment program, 8 manufacturing sites in drug product/sterile F&F and drug substance for a pharma multinational (TOP 5). Search of a global licensing partner for a midsize US based specialty pharma business. Identification of potential acquisition opportunities for private equity and biopharmaceutical CDMOs and suppliers in innovative markets such as cell and gene therapy.
Leading M&A, Strategy and New Business Development activities for Lianhetech, a Shenzhen listed (USD c. 2bn market cap) company operating in Pharma-, Agro- and Performance Chemicals (Turnover c. USD 700m). Responsible for leading direct reports and cross-functional teams. Creation of strategic and financial plan in collaboration with the finance and commercial organization. Creation of a deal pipeline with more than 100 potential acquisition targets and 10 viable M&A options in Europe. Execution of first outbound acquisition in Europe (Transaction consideration - c. USD 150m) incl. offshore financing and cash management concept with banks. Negotiation of transaction agreements (debt financing and share purchase)
Responsibility for the Global Business Development team with direct and indirect reports of the Chemicals Division in four business units: Homogenous catalysis, heterogenous catalysis, drug substance contract manufacturing and precious metals recycling (c. 1500 employees / c. EBIT EUR 100m). Target identification and execution of strategic transactions such as M&A, licensing, strategic partnerships and commercial collaborations. Development and implementation of strategic planning process.